Additionally, LINC00330 in the ESCC TME can also inhibit the formation of CCL2-mediated M2 TAMs, promoting the reprogramming of ESCC TAMs into anticancer M1 TAMs and further reducing the malignancy of ESCC. This evidence concerns the gene CCL2 and esophageal squamous cell carcinoma.